ESTRO 2024 - Abstract Book

S1086

Clinical - Gynaecology

ESTRO 2024

without lymphadenectomy, according to pre-surgery risk group. Patients received adjuvant treatment with brachytherapy, external beam radiotherapy and chemotherapy based on pathological findings.

Patients with clinical progression were presented at gynecological multidisciplinary committee and salvage or palliative treatment were discussed. Impact in overall survival of salvage treatment and pathological and molecular factors at diagnosis were analyzed in these subgroup of patients. Statistical analysis were performed with Kaplan Meier models with SPSS v25.

Results:

A series of 724 patients treated with primary endometrial cáncer from 2009 to 2018 were included. 102 patients (14.0%) presented recurrence from the disease during this period.

After diagnosis 24 patients (23.53%) were treated only with surgery, 21 patients (20.59%) were treated with adjuvant brachytherapy, 57 patients (55.88%) completed treatment with external beam radiotherapy, brachytherapy and chemotherapy. Histology groups were endometrial carcinoma in 48 patients (47.06%), serous or clear cell carcinoma in 25 patients (24.51%) and others in 29 patients (28.43%). Risk groups were low risk in 17 patients (16.67%), intermediate risk in 1 patient (0.98%), high-intermediate risk in 24 patients (23.53%) and high risk in 60 patients (58.82%). We analyze molecular and pathological and molecular factors in Table 1 . At time of relapse the mean age was 70.5 years (37-93). Relapses were local in 22 patients (21.59%), lymph node relapses occur in 9 patients (8.8%) and metastatic relapses in 71 patients (69.61%). After recurrents of the disease 43 patients (42.16%) received palliative chemotherapy, 14 (13.73%) palliative radiotherapy, 5 (4.9%) palliative surgery and 19 (18.63%) received no treatment. 14 patients (13.73%) received salvage treatment with surgery, external beam radiotherapy or brachytherapy. With a median follow-up of 83.5 months (15-155), 84 patients (82.0%) were dead, 75 of them (73.5%) because of the disease. 5 year overall survival was 14.5%: 9.6% for palliative treatment and 47.5% for salvage treatment (log rank test p=0.01; Image1 ). Presence of LVSI at diagnosis (log rank test p=0.35) or p53 (log rank test p=0.339) had no impact on overall survival.

Table 1.

Image 1